BioCentury
ARTICLE | Company News

FDA reviewing Emmaus' sickle cell therapy

November 8, 2016 11:52 PM UTC

Emmaus Life Sciences Inc. (Torrance, Calif.) said FDA accepted an NDA for its pharmaceutical-grade L-glutamine to treat sickle cell disease. The company said it is awaiting notice from FDA regarding its Priority Review request for the product.

In 2014, Emmaus said the candidate met the primary endpoint of reducing median frequency of sickle cell crises in a Phase III trial (see BioCentury Extra, March 19, 2014)...

BCIQ Company Profiles

Emmaus Life Sciences Inc.